Yorktown Management & Research Company’s Madrigal Pharmaceuticals MDGL Stock Holding History

Yorktown Management & Research Company’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$268K	Buy	+500	New	+$256K	0.16%	227

Other funds holding MDGL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

EAM

EULAV Asset Management Sarasota, Florida $3.13B AUM 23.04% 1-Year Est. Return

Yorktown Management & Research Company's MDGL Position: Q2 2026 in Review

Yorktown Management & Research Company opened a new position in Madrigal Pharmaceuticals (MDGL) in Q2 2026: 500 shares worth $268K. The stake represents 0.16% of the portfolio and ranks #227 among its holdings.

167 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

Yorktown Management & Research Company held 500 shares of Madrigal Pharmaceuticals worth $268K as of Q2 2026.
Madrigal Pharmaceuticals was a new Yorktown Management & Research Company position in Q2 2026.
Madrigal Pharmaceuticals made up 0.16% of Yorktown Management & Research Company's portfolio in Q2 2026, its #227 holding.
167 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Yorktown Management & Research Company's 13F filing for Q2 2026, filed 23 Jul 2026.